Hologic price target raised to $100 from $95 at Raymond James

Raymond James analyst Andrew Cooper raised the firm’s price target on Hologic to $100 from $95 and keeps an Outperform rating on the shares. Hologic’s Q2 results topped estimates across the board and guidance was raised for the year, but implies a modestly lower 2H than previously expected, the analyst tells investors in a research note. At the same time, management pointed not just to double-digit growth in all segments this year, but to durability of growth drivers thereafter, the firm says.